Skip to main content

Clitoral Phimosis and Clitoral Adhesions

Clitoral phimosis is the inability to retract the clitoral prepuce (clitoral hood) to expose the entire glans clitoris. It is a distinct entity from clitoral adhesions, in which the prepuce is directly tethered to the glans by epithelial bridging. Either may be asymptomatic or associated with trapped keratin / smegma, periclitoral pseudocysts or pain. Sexual symptoms require a broader assessment. Scarring may be an architectural sequela of vulvar lichen sclerosus (LS).[1][2][3]

For the underlying dermatologic disease, see Lichen Sclerosus. For aesthetic clitoral-hood reduction in the absence of pathologic phimosis, see Inverted-Y Clitoral Hoodoplasty and Liu Classification Hoodoplasty; those are cosmetic procedures.

For other causes of focal clitoral symptoms or enlargement, see Clitoral Pain, Priapism and Enlargement; Clitoral Anatomy and Physiology covers the glans and dorsal neurovascular course.

Definition and Classification​

A 2025 international Delphi consensus (Krapf et al.) standardized terminology:[1]

  • Clitoral phimosis. Inability to retract the prepuce to expose the entire glans clitoris.
  • Clitoral adhesions. Direct tethering of the prepuce to the glans clitoris.
  • The degree of phimosis should be classified as mild, moderate, or severe, and described as partially retractable or completely non-retractable.
  • Both prepuce characteristics and glans size should be documented.

The two entities frequently coexist (phimotic prepuce with bridging adhesions to the glans beneath) and treatment depends on symptoms and underlying disease. Selected symptomatic adhesions may be lysed in the office; persistent symptomatic scar-related phimosis may warrant specialist surgical release.[1][4]

Prevalence​

PopulationRate
3,650 sexually active heterosexual women aged 20–45 (Czech cohort)1.3% (46 women) had some form of clitoral phimosis; severe in 9[5]
Sexual-dysfunction clinic referrals22% in the cited referral cohort[2]
Sexual medicine practice, retrospective vulvoscopy review (614 evaluable patients)23% had clitoral adhesions (mild 44%, moderate 34%, severe 22%); 14% of the adhesion group presented with clitorodynia[20]

Etiology​

CauseNotes
Lichen sclerosus (LS)LS causes chronic inflammation and epithelial thinning; plaques may extend in a figure-of-eight pattern over the vulva, perineum, and perianal skin, while advanced scarring may resorb the labia minora and bury the clitoral glans beneath the hood.[3][6]
Lichen planus (LP)Similar scarring mechanism with mucosal involvement[7]
Genitourinary syndrome of menopause (GSM)Hypoestrogenic vulvar changes may include clitoral-hood phimosis.[3]
Recurrent vulvar dermal infections / blunt traumaProposed by the authors of the referral-clinic study to alter preputial elasticity[2]
Other associated factorsA retrospective vulvoscopy cohort found clitoral adhesions associated with a history of sexual pain, yeast infection, urinary tract infection, blunt perineal or genital trauma, lichen sclerosus, low calculated free testosterone, and other sexual dysfunctions including persistent genital arousal disorder[20]
Congenital fusionRare; can present as a periclitoral mass from trapped sebaceous material[8]
Anatomic predispositionHistologic study found that the clitoral glandopreputial sulcus usually remains partly closed, unlike the penile sulcus; the authors proposed that this anatomy may contribute to some cases of phimosis, cysts, and pilonidal sinuses.[9]

Clinical Presentation​

  • Sexual dysfunction. Decreased clitoral sensation, impaired arousal, anorgasmia, and dyspareunia. Most consistent in severe LS-related phimosis.[5][10] A retrospective vulvoscopy cohort found clitorodynia in 14% of women with clitoral adhesions.[20]
  • Sexual pain. The only symptom the referral-clinic study linked to phimosis; it found no correlation with desire, arousal or orgasm disorders.[2]
  • Smegma or keratin pearl accumulation beneath the fused prepuce: palpable mass that can mimic vulvar malignancy.[8][11]
  • Pseudocyst formation. A sealed clitoral hood can trap smegma and other debris, forming a pseudocyst; infection may require drainage or antibiotics.[10][23] Eccrine duct cystic dilatation has also been described histologically.[9]
  • Pediatric or adolescent LS. Atrophic change can include clitoral phimosis, labial resorption, or adhesions; in a 15-patient series, separate adolescents required surgery for urinary retention and for dyspareunia caused by clitoral entrapment.[12]

Diagnosis​

  • Exam-based. Cephalad displacement of the labia minora to retract the prepuce. Inability to fully expose the glans confirms the diagnosis.[2]
  • Document phimosis versus adhesion. Phimosis limits full preputial retraction; adhesions tether the prepuce to the glans.[1] Symptomatic adhesions may be lysed in the office.[4]
  • Biopsy any new hyperkeratotic lesion, erosion, ulceration, or suspicious mass in a patient with LS; biopsy may also clarify an uncertain diagnosis or treatment failure. Continue vulvar surveillance for LS-associated SCC.[22][6]
  • Examine the clitoris in patients with sexual dysfunction, vulvar symptoms, or known vulvar dermatoses. In patients with clitorodynia, look for adhesions, debris, or keratin pearls and assess pelvic-floor muscle tone and possible neuropathic causes of pain.[4][24]

A keratin pearl is a firm focus of keratin trapped between the prepuce and glans; it can be painful even when the prepuce is partly retractable. Distinguish it from a separate enlarging cyst or suspicious vulvar lesion before offering lysis.[15][24]

Treatment Ladder​

Treatment is guided by severity, symptom burden, and underlying etiology; asymptomatic adhesions do not automatically require intervention. For LS-related vulvar surgery, a 2026 German S3 guideline strongly recommends agreement on topical treatment before and after surgery and interdisciplinary counselling that includes pelvic-floor physiotherapy and sex therapy; it suggests against surgery in girls except selected functional impairment.[22] For women with LS-related introital stenosis that impairs voiding or intercourse despite guideline-conform topical corticosteroids, the S3 guideline suggests de-adhesion, perineoplasty, or anatomic vulvoplasty.[22] BAD guidance supports treatment of inflammation and selective surgery for troublesome scarring.[14] Most patients require ongoing dermatologic maintenance even after a successful procedure because the underlying LS / LP is chronic.[7][10]

1. Medical (first-line for the underlying dermatosis)​

  • High-potency topical corticosteroids. An individualized induction and maintenance regimen (see the linked LS page). Prevents progression but does not reverse established architectural changes.[3][6][12]
  • Maintenance for LS or LP. Continue individualized anti-inflammatory treatment after release when an inflammatory dermatosis is present; routine steroid use solely to prevent readhesion without LS or LP has not been established.[7][3][4]
  • LS regimen. The BASHH 2024 vulval guideline gives clobetasol ointment once daily for four weeks, on alternate days for four weeks, then twice weekly for four weeks, followed by maintenance adjusted to examination and symptoms.[23] In a 507-patient vulvar-LS cohort, adherent versus partially adherent patients had symptom suppression in 93.3% versus 58.0% and progression of adhesions or scarring in 3.4% versus 40.0% during follow-up.[25]
  • Hypoestrogenic tissue. When genitourinary syndrome of menopause contributes to thin, dry vulvar tissue, address the estrogen deficiency separately from any fixed adhesion. Topical estrogen is used after lysis of postmenopausal labial fusion; in a 14-patient series, estrogen-only maintenance was followed by recurrence in 3 of 3 patients, while a later estrogen-plus-dilation protocol had no recurrence over a mean 24 months.[27]
  • Topical testosterone is not a substitute. In the Cochrane review of genital LS, four trials found no significant benefit from topical testosterone, dihydrotestosterone or progesterone, and testosterone used as maintenance after clobetasol worsened symptoms; a retrospective series found higher symptom-response rates at 6 months with clobetasol 0.05% than with testosterone 2% (91.7% versus 77.5%) and lower recurrence (6.7% versus 20%).[17][19]

2. Office lysis of symptomatic adhesions​

Select patients with a visible or palpable adhesion, trapped debris or pearl, and a symptom plausibly localized to that finding. Document the amount of exposed glans, tenderness, and coexisting LS or hypoestrogenic change. After consent, topical anesthetic and/or a dorsal clitoral nerve block can provide local anesthesia; assess effect before manipulation. Fine Jacobsen mosquito forceps separate the prepuce from the glans in the adhesion plane. Remove exposed smegma or keratin pearls; the endpoint is full visualization of the glans and corona without deep dissection into the body or dorsal bundle.[4][24]

In the Myers 2022 retrospective series, 41 of 61 eligible patients responded (67%); the following are respondent-reported outcomes without a control group or validated pre-post instrument:[4]

  • 76% (19/25 pain-item respondents) reported pain improvement [4]
  • 63% (25/40) reported improved arousal [4]
  • 64% (25/39) reported improved orgasmic function [4]
  • 38% (6/16) who had been unable to reach orgasm with external clitoral stimulation reported doing so afterward [4]
  • 83% (34/41) were satisfied with their decision to undergo lysis [4]
  • 93% of survey respondents would recommend the procedure [4]

In a later pre-post study of women with partial clitoral phimosis and keratin pearls, 32 of 74 eligible patients responded after office lysis with pearl excision. Among respondents, mean clitoral pain fell from 6.9 to 2.5 on an 11-point scale and FSFI rose from 12.1 to 17.7; 28% reported recurrence, with a median of 2 repeat procedures.[15] A 2026 meta-analysis of these interventions was retracted after an error in the Krapf sample size propagated through its analyses.[16] Counsel about pain and recurrence: among 41 Myers survey respondents, 27% recalled procedural pain, 54% painful recovery, 46% recurrent adhesions, and 24% repeat lysis.[4]

Fixed scar-related preputial narrowing needs a separate specialist assessment; neither finding by itself mandates a procedure.

3. Surgical management (persistent symptomatic phimosis)​

Clitoral circumcision / prepucectomy​

Goldstein and Burrows described lacrimal-probe adhesiolysis followed by an approximately 5-mm dorsal preputial incision without tissue excision; Chmel reported clitoral circumcision in nine women with severe phimosis.[10][5] Small uncontrolled reports describe Goldstein and Burrows (8 women with LS; 88% very satisfied, and all 4 with reduced preoperative clitoral sensation regained sensation and orgasm)[10] and Chmel (9 women with severe phimosis, 12-month follow-up); comparative outcomes are unavailable:[5]

  • FSFI improved from 17.9 to 26.6 at 12 months (p < 0.001)
  • Significant improvement in arousal, orgasm, and dyspareunia domains
  • Concurrent perineoplasty may be required when introital stenosis coexists (2 of 9).[5]

In a 2026 cohort of mixed LS surgery for introital stenosis or clitoral phimosis, 86 of 148 identified patients responded and 71 had paired FSFI scores rising from 15.0 to 22.7. Among the 86 respondents, 80 (93%) were satisfied, 29 (33.7%) reported recurrent scarring, and 9 (10.5%) underwent revision a mean 3.9 years after initial surgery; the mean surgery-to-survey interval was 4.35 years. Clitoral-only outcomes were not reported. It had no control group.[18]

For severe fixed phimosis, one described technique examines the opening under magnification and, when an opening is present, uses a lacrimal probe to identify and orient the clitoris beneath the fused hood. A skin incision is placed lateral and parallel to the clitoral body, stopping at Colles' fascia, and sharp lateral-to-medial dissection separates the body from the scar and mobilizes it toward the glans; the fused hood and frenulum are removed while the clitoral body is preserved, the vascular frenular junction is secured, and the subcutaneous layer is closed over the repositioned clitoris. This sequence has been described by Baggish; no comparative sensory, pain or sexual-function outcomes are reported for it.[21]

CO₂ laser preputial release​

Used for clitoral phimosis secondary to LS or LP with individualized pre- and postoperative topical therapy. Kroft and Shier series of 23 women:[7]

  • Mild reagglutination occurred in 5 of 20 LS patients.
  • 5 of 23 patients required reoperation (3 with LS, 2 with LP).
  • Overall satisfaction was high.

Surgicel application after lysis​

In a three-adolescent LS case report, oxidized regenerated cellulose (Surgicel) was sutured to the exposed clitoral-hood and labial surfaces after sharp lysis; none had recurrence at one year, without a comparator to show that the material prevented it.[11]

Two postmenopausal patients with labial and clitoral-hood agglutination had oxidized regenerated cellulose sutured over the separated surfaces; neither had reagglutination after more than 18 months.[26] This barrier approach has been reported for dense recurrent fusion after sharp separation, whereas thin prepuce-to-glans adhesions are generally separated bluntly in the office.[11][26][4]

Postoperative Considerations​

  • Reagglutination is a reported failure mode. Mild reagglutination occurred in 5 of 20 women with LS after CO₂ laser release[7]; recurrent adhesions were reported by 19 of 41 (46%) after office lysis in Myers[4] and by 28% of 32 respondents after office lysis with keratin-pearl excision.[15]
  • Continued topical treatment for LS or LP is part of postoperative care for the underlying dermatosis.[10][7] In one mixed vulvar-adhesion surgery cohort, patients applied clobetasol 0.05% to surgical sites daily until healing and then twice weekly; they were instructed to retract the clitoral prepuce and introital surgical sites four to six times daily during healing. [18]
  • Counsel about perioperative harms. In a mixed LS-surgery cohort, reported events included anesthesia or positioning problems, urinary symptoms or infection, and bleeding requiring a suture.[18]
  • Periodic surveillance examination for both reagglutination and the lifelong vulvar SCC risk in patients with LS.[6]

Key Principles​

  • Clitoral phimosis is distinct from clitoral adhesions; the Krapf 2025 Delphi consensus standardized this distinction.[1]
  • LS is an important cause; treat the underlying dermatosis with maintenance topical steroids regardless of whether a procedure is offered.[3][6]
  • Symptomatic adhesions may be treated with office lysis; persistent symptomatic scar-related phimosis may require surgical release after control of inflammation.[4][1]
  • Aesthetic clitoral hood reduction is an elective cosmetic procedure; phimosis release addresses symptomatic preputial scarring or adhesions.[13][18]
  • Reagglutination occurs after laser release and office lysis, with reported recurrence varying across cohorts and procedures. Continue disease-directed anti-inflammatory treatment when LS or LP is present.[7][4][15]
  • Biopsy suspicious lesions in any LS patient; continue surveillance for LS-associated vulvar SCC.[6]
  • Pediatric LS can produce lasting architectural changes. In a 15-patient referral series, 7 girls had atrophic changes at presentation, and the median delay to diagnosis was 7 months.[12]
  • Offer a consented clitoral examination when assessing relevant sexual symptoms or vulvar disease.[5][2]

See Also​

References​

1. Krapf JM, Pope R, Rubin RS, Moss CF, Mauskar MM. Definition and classification of clitoral phimosis and adhesions: an international Delphi study. BJOG. 2026;133(3):514-519. doi:10.1111/1471-0528.70066.

2. Munarriz R, Talakoub L, Kuohung W, et al. The prevalence of phimosis of the clitoris in women presenting to the sexual dysfunction clinic: lack of correlation to disorders of desire, arousal and orgasm. J Sex Marital Ther. 2002;28 Suppl 1:181-5. doi:10.1080/00926230252851302.

3. Ringel NE, Iglesia C. Common benign chronic vulvar disorders. Am Fam Physician. 2020;102(9):550-557. PMID 33118795

4. Myers MC, Romanello JP, Nico E, et al. A retrospective case series on patient satisfaction and efficacy of non-surgical lysis of clitoral adhesions. J Sex Med. 2022;19(9):1412-1420. doi:10.1016/j.jsxm.2022.06.011.

5. Chmel R, Nováčková M, Fait T, et al. Clitoral phimosis: effects on female sexual function and surgical treatment outcomes. J Sex Med. 2019;16(2):257-266. doi:10.1016/j.jsxm.2018.12.012.

6. Committee on Practice Bulletins–Gynecology. Diagnosis and management of vulvar skin disorders: ACOG Practice Bulletin, Number 224. Obstet Gynecol. 2020;136(1):e1-e14. doi:10.1097/AOG.0000000000003944.

7. Kroft J, Shier M. A novel approach to the surgical management of clitoral phimosis. J Obstet Gynaecol Can. 2012;34(5):465-471. doi:10.1016/S1701-2163(16)35243-4.

8. Maybury EK, Recio FO, Ahmad S, McKenzie ND. Fused clitoral hood presenting as a periclitoral mass. Obstet Gynecol. 2022;140(6):1056-1060. doi:10.1097/AOG.0000000000004996.

9. van der Putte SC, Sie-Go DM. Development and structure of the glandopreputial sulcus of the human clitoris with a special reference to glandopreputial glands. Anat Rec (Hoboken). 2011;294(1):156-64. doi:10.1002/ar.21279.

10. Goldstein AT, Burrows LJ. Surgical treatment of clitoral phimosis caused by lichen sclerosus. Am J Obstet Gynecol. 2007;196(2):126.e1-4. doi:10.1016/j.ajog.2006.08.023.

11. Breech LL, Laufer MR. Surgicel in the management of labial and clitoral hood adhesions in adolescents with lichen sclerosus. J Pediatr Adolesc Gynecol. 2000;13(1):21-2. doi:10.1016/s1083-3188(99)00029-7.

12. Nerantzoulis I, Grigoriadis T, Michala L. Genital lichen sclerosus in childhood and adolescence — a retrospective case series of 15 patients: early diagnosis is crucial to avoid long-term sequelae. Eur J Pediatr. 2017;176(10):1429-1432. doi:10.1007/s00431-017-3004-y.

13. American College of Obstetricians and Gynecologists. Elective female genital cosmetic surgery: ACOG Committee Opinion, Number 795. Obstet Gynecol. 2020;135(1):e36-e42. doi:10.1097/AOG.0000000000003616.

14. Lewis FM, Tatnall FM, Velangi SS, et al. British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. Br J Dermatol. 2018;178:839–853. doi:10.1111/bjd.16241.

15. Krapf JM, Kopits I, Holloway J, et al. Efficacy of in-office lysis of clitoral adhesions with excision of keratin pearls on clitoral pain and sexual function: a pre-post interventional study. J Sex Med. 2024;21(5):443-451. doi:10.1093/jsxmed/qdae034.

16. Retracted: Zulfikaroglu EE, Kurban D. Interventions for clitoral adhesions/phimosis in adult women: a systematic review and meta-analysis of sexual function, pain, and recurrence. Int Urogynecol J. 2026. doi:10.1007/s00192-026-06704-6.

17. Chi CC, Kirtschig G, Baldo M, et al. Topical interventions for genital lichen sclerosus. Cochrane Database Syst Rev. 2011;2011(12):CD008240. doi:10.1002/14651858.CD008240.pub2.

18. Krapf JM, Ghosalkar E, Goldstein A, et al. Lysis of vulvar adhesions and sexual function in vulvar lichen sclerosus. O G Open. 2026;3(4):e189. doi:10.1097/og9.0000000000000189.

19. Ayhan A, Guven S, Guvendag Guven ES, et al. Topical testosterone versus clobetasol for vulvar lichen sclerosus. Int J Gynaecol Obstet. 2007;96(2):117-21. doi:10.1016/j.ijgo.2006.09.018.

20. Aerts L, Rubin RS, Randazzo M, Goldstein SW, Goldstein I. Retrospective study of the prevalence and risk factors of clitoral adhesions: women's health providers should routinely examine the glans clitoris. Sex Med. 2018;6(2):115-122. doi:10.1016/j.esxm.2018.01.003.

21. Baggish MS. Correction of clitoral phimosis. In: Baggish MS, Karram MM, eds. Atlas of Pelvic Anatomy and Gynecologic Surgery. 5th ed. Elsevier; 2021:967-970.

22. Kirtschig G, Woelber L, Günthert A, et al. "Evidence- and consensus-based guideline on lichen sclerosus." J Dtsch Dermatol Ges. 2026;24(4):566-584. doi:10.1111/ddg.70000

23. Edwards SK, Lewis F, Fernando I, Haddon L, Grover D. "2024 British Association for Sexual Health and HIV (BASHH) UK national guideline on the management of vulval conditions." Int J STD AIDS. 2025;36(5):346-371. doi:10.1177/09564624241311629

24. Krapf JM, Pope R. "Approach to diagnosis and management of clitorodynia." O G Open. 2025;2(1):e062. doi:10.1097/og9.0000000000000062

25. Lee A, Bradford J, Fischer G. "Long-term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women." JAMA Dermatol. 2015;151(10):1061-1067. doi:10.1001/jamadermatol.2015.0643

26. Wyman AM, Lafranchise E, Lynch C. "External use of an oxidized regenerated cellulose agent in the treatment of labial agglutination in postmenopausal women." Obstet Gynecol. 2018;132(5):1238-1240. doi:10.1097/AOG.0000000000002919

27. Ibanez RF, Fernandez M, Palavoor Naduvakkat P, Dominguez-Bali A. "Postmenopausal labial adhesion: a 5-stage classification system and clinical outcomes in a 14-patient series." Maturitas. 2026;205:108823. doi:10.1016/j.maturitas.2025.108823